Erythropoietin: A hormone with multiple functions

Pathobiology

Volumn 78, Issue 1, 2011, Pages 41-56

  Lombardero, Matilde ^a   Kovacs, Kalman ^b   Scheithauer, Bernd W ^c  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Erythropoietin, receptor; Ischemia; Neoplasm

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR;

ANGIOGENESIS; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DIARRHEA; DYSPNEA; EDEMA; ERYTHROPOIESIS; FEVER; HEART PROTECTION; HUMAN; IMMUNE RESPONSE; ISCHEMIA; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; OXYGEN SUPPLY; PARESTHESIA; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; ERYTHROPOIESIS; ERYTHROPOIETIN; HUMANS; KIDNEY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ERYTHROPOIETIN;

MAMMALIA;

EID: 79953842857     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322975     Document Type: Review

References (151)

1. Maxwell PH, Ferguson DJ, Nicholls LG, Iredale JP, Pugh CW, Johnson MH, Ratcliffe PJ: Sites of erythropoietin production. Kidney Int 1997; 51: 393-401. (Pubitemid 27088149)
2. Sasaki R, Masuda S, Nagao M: Erythropoietin: multiple physiological functions and regulation of biosynthesis. Biosci Biotechnol Biochem 2000; 64: 1775-1793.
3. Maiese K, Li F, Chong ZZ: New avenues of exploration for erythropoietin. JAMA 2005; 293: 90-95. (Pubitemid 40066704)
4. Lappin T: The cellular biology of erythropoietin receptors. Oncologist 2003; 8: 15-18. (Pubitemid 36331743)
5. Dordal MS, Wang FF, Goldwasser E: The role of carbohydrate in erythropoietin action. Endocrinology 1985; 116: 2293-2299. (Pubitemid 15098058)
6. Lacombe C, Mayeux P: Biology of erythropoietin. Haematologica 1998; 83: 724-732. (Pubitemid 28492155)
7. Mulcahy L: The erythropoietin receptor. Semin Oncol 2001; 28(suppl 8):19-23. (Pubitemid 32522233)
8. Yoshimura A, Arai K: Physician education: the erythropoietin receptor and signal transduction. Oncologist 1996; 1: 337-339.
9. Lacombe C, Mayeux P: The molecular biology of erythropoietin. Nephrol Dial Transplant 1999; 14(suppl 2):22-28. (Pubitemid 29154936)
10. Rossert J, Eckardt KU: Erythropoietin receptors: their role beyond erythropoiesis. Nephrol Dial Transplant 2005; 20: 1025-1028. (Pubitemid 40862086)
11. Fraser JK, Lin FK, Berridge MV: Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line, HEL. Exp Hematol 1988; 16: 836-842.
12. Broudy VC, Lin N, Egrie J, de Haën C, Weiss T, Papayannopoulou T, Adamson JW: Identification of the receptor for erythropoietin on human and murine erythroleukemia cells and modulation by phorbol ester and dimethyl sulfoxide. Proc Natl Acad Sci USA 1988; 85: 6513-6517.
13. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M: Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990; 87: 5978-5982.
14. Sawyer ST, Krantz SB, Goldwasser E: Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J Biol Chem 1987; 262: 5554-5562.
15. Hitomi K, Fujita K, Sasaki R, Chiba H, Okuno Y, Ichiba S, Takahashi T, Imura H: Erythropoietin receptor of a human leukemic cell line with erythroid characteristics. Biochem Biophys Res Commun 1988; 154: 902-909.
16. Mayeux P, Billat C, Jacquot R: The erythropoietin receptor of rat erythroid progenitor lens: characterization and affinity crosslinkage. J Biol Chem 1987; 262: 13985-13990.
17. Chong ZZ, Kang JQ, Maiese K: Angiogenesis and plasticity: role of erythropoietin in vascular systems. J Hematother Stem Cell Res 2002; 11: 863-871. (Pubitemid 36139767)
18. Fandrey J: Oxygen-dependent and tissuespecific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 2004; 286:R977-R988. (Pubitemid 38661383)
19. Stockmann C, Fandrey J: Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression. Clin Exp Pharmacol Physiol 2006; 33: 968-979. (Pubitemid 44429878)
20. Hewitson KS, McNeill LA, Schofield CJ: Modulating the hypoxia-inducible factor signaling pathway: applications from cardiovascular disease to cancer. Curr Pharm Des 2004; 10: 821-833. (Pubitemid 38380061)
21. Maxwell AP, Lappin TR, Johnston CF, Bridges JM, McGeown MG: Erythropoietin production in kidney tubular cells. Br J Haematol 1990; 74: 535-539. (Pubitemid 20122759)
22. Burlington H, Cronkite EP, Reincke U, Zanjani ED: Erythropoietin production in cultures of goat renal glomeruli. Proc Natl Acad Sci USA 1972; 69: 3547-3550.
23. Kurtz A, Jelkmann W, Sinowaitz F, Bauer C: Renal mesangial cell cultures as a model for study of erythropoietin production. Proc Natl Acad Sci USA 1983; 80: 4008-4011. (Pubitemid 13072775)
24. Lacombe C, Da Silva JL, Bruneval P, Fournier JG, Wendling F, Casadevall N, Camilleri JP, Bariety J, Varet B, Tambourin P: Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 1988; 81: 620-623. (Pubitemid 18075261)
25. Koury ST, Bondurant MC, Koury MJ: Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988; 71: 524-527. (Pubitemid 18089550)
26. Schuster SJ, Wilson JH, Erselv AJ, Caro J: Cellular sites of extrarenal and renal erythropoietin production in anaemic rats. Br J Haematol 1992; 81: 153-159.
27. Bachmann S, Le HM, Eckardt KU: Co-localization of erythropoietin mRNA and ecto- 5′-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 1993; 41: 335-341. (Pubitemid 23061919)
28. Maxwell PH, Osmond MK, Pugh CW, Heryet A, Nicholls LG, Tan CC, Doe BG, Ferguson DJ, Johnson MH, Ratcliffe PJ: Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 1993; 44: 1149-1162. (Pubitemid 23316488)
29. Obara N, Suzuki N, Kim K, Nagasawa T, Imagawa S, Yamamoto M: Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 2008; 111: 5223-5232.
30. Koury ST, Koury MJ, Bondurant MC, Caro J, Graber SE: Quantitation of erythropoietinproducing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood 1989; 74: 645-651. (Pubitemid 19208805)
31. Krantz SB: Erythropoietin. Blood 1991; 77: 419-434.
32. Jelkmann W: Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72: 449-489.
33. Koury ST, Bondurant MC, Koury MJ, Semenza GL: Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 1991; 77: 2497-2503.
34. Maxwell PH, Ferguson DJ, Osmond MK, Pugh CW, Heryet A, Doe BG, Johnson MH, Ratcliffe PJ: Expression of a homologously recombined erythropoietin-SV40 T antigen fusion gene in mouse liver: evidence for erythropoietin production by Ito cells. Blood 1994; 84: 1823-1830. (Pubitemid 24286131)
35. Brines M, Cerami A: Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006; 70: 246-250. (Pubitemid 44086573)
36. Fisher JW: Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 2003; 228: 1-14. (Pubitemid 36077622)
37. Gregory CJ, Eaves AC: Three stages of erythropoietic progenitor cell differentiation distinguished by a number of physical and biologic properties. Blood 1978; 51: 527-537. (Pubitemid 8298485)
38. Jelkmann W: Molecular biology of erythropoietin. Intern Med 2004; 43: 649-659. (Pubitemid 39264162)
39. Wu H, Liu X, Jaenisch R, Lodish HF: Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83: 59-67.
40. Lin CS, Lim SK, D'Agati V, Costantini F: Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev 1996; 10: 154-164.
41. Eckardt KU, Kurtz A: Regulation of erythropoietin production. Eur J Clin Invest 2005; 35(suppl 3):13-19. (Pubitemid 41783599)
42. Pfeilschifter J, Huwiler A: Erythropoietin is more than just a promoter of erythropoiesis. J Am Soc Nephrol 2004; 15: 2240-2241. (Pubitemid 39031364)
43. Robinson N, Giraud S, Saudan C, Baume N, Avois L, Mangin P, Saugy M: Erythropoietin and blood doping. Br J Sports Med 2006; 40(suppl 1):i30-i34. (Pubitemid 44032628)
44. Jelkmann W: Erythropoiesis stimulating agents and techniques: a challenge for doping analysts. Curr Med Chem 2009; 16: 1236-1247.
45. Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F Jr, Tabira T, Sasaki R: Functional erythropoietin receptor of the cells with neural characteristics: comparison with receptor properties of erythroid cells. J Biol Chem 1993; 268: 11208-11216. (Pubitemid 23162313)
46. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R: Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997; 76: 105-116. (Pubitemid 26407940)
47. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R: A novel site of erythropoietin production: oxygen-dependent production in cultured rat astrocytes. J Biol Chem 1994; 269: 19488-19493.
48. Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V, Yonekawa Y, Bauer C, Gassmann M: Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996; 8: 666-676. (Pubitemid 26114611)
49. Li X, Gonias SL, Campana WM: Schwann cells express erythropoietin receptor and represent a major target for Epo in peripheral nerve injury. Glia 2005; 51: 254-265. (Pubitemid 41532101)
50. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT: Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994; 91: 3974-3978. (Pubitemid 24139555)
51. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT: Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004; 104: 2073-2080. (Pubitemid 39297859)
52. Heidenreich S, Rahn KH, Zidek W: Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991; 39: 259-265.
53. Morakkabati N, Gollnick F, Meyer R, Fandrey J, Jelkmann W: Erythropoietin induces Ca 2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp Hematol 1996; 24: 392-397. (Pubitemid 26096314)
54. Ammarguellat F, Gogusev J, Drüeke TB: Direct effect of erythropoietin on rat vascular smooth-muscle cell via a putative erythropoietin receptor. Nephrol Dial Transplant 1996; 11: 687-692. (Pubitemid 26114553)
55. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox- Talbot K, Lu H, Zweier JL, Semenza GL: Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003; 108: 79-85. (Pubitemid 36859024)
56. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El-Sherif N: Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003; 308: 990-994. (Pubitemid 36976556)
57. Sinclair AM, Coxon A, McCaffery I, Kaufman S, Paweletz K, Liu L, Busse L, Swift S, Elliott S, Begley CG: Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 2010; 115: 4264-4272.
58. Sereno M, García-Cabezas MA, De Castro J, Cejas P, Saenz EC, Belda-Iniesta C, Feijoo JB, Larrauri J, Nistal M, Baron MG: Immunohistochemical expression of p53, Bcl-2, COX-2, C-erb-B2, EPO-R, beta-catenin, and E-cadherin in non tumoral gastric mucous membrane. Eur J Histochem 2006; 50: 285-292. (Pubitemid 351480090)
59. Juul SE, Ledbetter DJ, Joyce AE, Dame C, Christensen RD, Zhao Y, DeMarco V: Erythropoietin acts as a trophic factor in neonatal rat intestine. Gut 2001; 49: 182-189. (Pubitemid 32675109)
60. McPherson RJ, Juul SE: High-dose erythropoietin inhibits apoptosis and stimulates proliferation in neonatal rat intestine. Growth Horm IGF Res 2007; 17: 424-430. (Pubitemid 47324310)
61. Fenjves ES, Ochoa MS, Cabrera O, Mendez AJ, Kenyon NS, Inverardi L, Ricordi C: Human, nonhuman primate, and rat pancreatic islets express erythropoietin receptors. Transplantation 2003; 75: 1356-1360. (Pubitemid 36513048)
62. Oztürk M, Ustek D, Akbas F, Kösem M, Abaci N, Alagöl F, Oztürk G, Kotan C: The presence of erythropoietin receptor in parathyroid cells. J Endocrinol Invest 2007; 30:RC35- 37. (Pubitemid 351350823)
63. Jelkmann W: Effects of erythropoietin on brain function. Curr Pharm Biotechnol 2005; 6: 65-79. (Pubitemid 40246754)
64. Yasuda Y, Fujita Y, Musha T, Tanaka H, Shiokawa S, Nakamatsu K, Mori S, Matsuo T, Nakamura Y: Expression of erythropoietin in human female reproductive organs. Ital J Anat Embryol 2001; 106(suppl 2):215-222.
65. Masuda S, Kobayashi T, Chikuma M, Nagao M, Sasaki R: The oviduct produces erythropoietin in an estrogen- and oxygen-dependent manner. Am J Physiol Endocrinol Metab 2000; 278:E1038-E1044. (Pubitemid 30439141)
66. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R: Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 1998; 273: 25381-25387. (Pubitemid 28443305)
67. Magnanti M, Gandini O, Giuliani L, Gazzaniga P, Marti HH, Gradilone A, Frati L, Aglianò AM, Gassmann M: Erythropoietin expression in primary rat Sertoli and peritubular myoid cells. Blood 2008; 98: 2872-2874.
68. Yamazaki T, Kanzaki M, Kamidono S, Fujisawa M: Effect of erythropoietin on Leydig cell is associated with the activation of Stat5 pathway. Mol Cell Endocrinol 2004; 213: 193-198. (Pubitemid 38210049)
69. Kobayashi T, Yanase H, Iwanaga T, Sasaki R, Nagao M: Epididymis is a novel site of erythropoietin production in mouse reproductive organs. Biochem Biophys Res Commun 2002; 296: 145-151. (Pubitemid 35002069)
70. Zhang Q, Zhang J, Moe OW, Hsia CC: Synergistic upregulation of erythropoietin receptor (EPO-R) expression by sense and antisense EPO-R transcripts in the canine lung. Proc Natl Acad Sci USA 2008; 105: 7612-7617. (Pubitemid 351830066)
71. Juul SE, Zhao Y, Dame JB, Du Y, Hutson AD, Christensen RD: Origin and fate of erythropoietin in human milk. Pediatr Res 2000; 48: 660-667.
72. Semba RD, Juul SE: Erythropoietin in human milk: physiology and role in infant health. J Hum Lact 2002; 18: 252-261.
73. Kling PJ: Roles of erythropoietin in human milk. Acta Paediatr Suppl 2002; 91: 31-35. (Pubitemid 35347059)
74. Carmichael RD, Gordon AS, Lobue J: Effects of the hormone erythropoietin in milk on erythropoiesis in neonatal rats. Endocrinol Exp 1986; 20: 167-188. (Pubitemid 17193729)
75. Brines M, Cerami A: Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005; 6: 484-494. (Pubitemid 40769173)
76. Maiese K, Chong ZZ, Hou J, Shang YC: Erythropoietin and oxidative stress. Curr Neurovasc Res 2008; 5: 125-142. (Pubitemid 351838578)
77. Contaldo C, Elsherbiny A, Lindenblatt N, Plock JA, Trentz O, Giovanoli P, Menger MD, Wanner GA: Erythropoietin enhances oxygenation in critically perfused tissue through modulation of nitric oxide synthase. Shock 2009; 31: 599-606.
78. Maxwell P: HIF-1: an oxygen response system with special relevance to the kidney. J Am Soc Nephrol 2003; 14: 2712-2722. (Pubitemid 37305633)
79. Burger D, Xenocostas A, Feng QP: Molecular basis of cardioprotection by erythropoietin. Curr Mol Pharmacol 2009; 2: 56-69.
80. Zhao ZQ, Velez DA, Wang NP, Hewan-Lowe KO, Nakamura M, Guyton RA, Vinten-Johansen J: Progressively developed myocardial apoptotic cell death during late phase of reperfusion. Apoptosis 2001; 6: 279-290. (Pubitemid 32708522)
81. Prass K, Scharff A, Ruscher K, Löwl D, Muselmann C, Victorov I, Kapinya K, Dirnagl U, Meisel A: Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 2003; 34: 1981-1986. (Pubitemid 36944794)
82. Baker JE: Erythropoietin mimics ischemic preconditioning. Vascul Pharmacol 2005; 42: 233-241. (Pubitemid 40726326)
83. Joyeux-Faure M: Cellular protection by erythropoietin: new therapeutic implications? J Pharmacol Exp Ther 2007; 323: 759-762. (Pubitemid 350146047)
84. Dawson TM: Preconditioning-mediated neuroprotection through erythropoietin? Lancet 2002; 359: 96-97 (erratum published in Lancet 2002; 359: 1782). (Pubitemid 34112534)
85. Ruscher K, Freyer D, Karsch M, Isaev N, Megow D, Sawitzki B, Priller J, Dirnagl U, Meisel A: Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 2002; 22: 10291-10301. (Pubitemid 35416867)
86. Marti HH, Bernaudin M, Petit E, Bauer C: Neuroprotection and angiogenesis: dual role of erythropoietin in brain ischemia. News Physiol Sci 2000; 15: 225-229.
87. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M: Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004; 35: 1732-1737. (Pubitemid 38823656)
88. Kaptanoglu E, Solaroglu I, Okutan O, Surucu HS, Akbiyik F, Beskonakli E: Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings. Neurosurg Rev 2004; 27: 113-120. (Pubitemid 38374415)
89. Hartley CE, Varma M, Fischer JP, Riccardi R, Strauss JA, Shah S, Zhang S, Yang ZJ: Neuroprotective effects of erythropoietin on acute metabolic and pathological changes in experimentally induced neurotrauma. J Neurosurg 2008; 109: 708-714.
90. Xiong Y, Lu D, Qu C, Goussev A, Schallert T, Mahmood A, Chopp M: Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice. J Neurosurg 2008; 109: 510-521.
91. Yin ZS, Zhang H, Gao W: Erythropoietin promotes functional recovery and enhances nerve regeneration after peripheral nerve injury in rats. AJNR Am J Neuroradiol 2010; 31: 509-515.
92. Shingo T, Sorokan ST, Shimazaki T, Weiss S: Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001; 21: 9733-9743. (Pubitemid 34184059)
93. Jing M, Shingo T, Yasuhara T, Kondo A, Morimoto T, Wang F, Baba T, Yuan WJ, Tajiri N, Uozumi T, Murakami M, Tanabe M, Miyoshi Y, Zhao S, Date I: The combined therapy of intrahippocampal transplantation of adult neural stem cells and intraventricular erythropoietin-infusion ameliorates spontaneous recurrent seizures by suppression of abnormal mossy fiber sprouting. Brain Res 2009; 1295: 203-217.
94. Malá H, Alsina CG, Madsen KS, Sibbesen EC, Stick H, Mogensen J: Erythropoietin improves place learning in an 8-arm radial maze in fimbria-fornix transected rats. Neural Plast 2005; 12: 329-340. (Pubitemid 43072008)
95. Chong ZZ, Li F, Maiese K: Employing new cellular therapeutic targets for Alzheimer's disease: a change for the better? Curr Neurovasc Res 2005; 2: 55-72. (Pubitemid 41419946)
96. Danielyan L, Schäfer R, Schulz A, Ladewig T, Lourhmati A, Buadze M, Schmitt AL, Verleysdonk S, Kabisch D, Koeppen K, Siegel G, Proksch B, Kluba T, Eckert A, Köhle C, Schöneberg T, Northoff H, Schwab M, Gleiter CH: Survival, neuron-like differentiation and functionality of mesenchymal stem cells in neurotoxic environment: the critical role of erythropoietin. Cell Death Differ 2009; 16: 1599-1614.
97. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ: A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112: 999-1007. (Pubitemid 38056315)
98. van der Meer P, Lipsic E, Henning RH, de Boer RA, Suurmeijer AJ, van Veldhuisen DJ, van Gilst WH: Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail 2004; 6: 853-859. (Pubitemid 39536300)
99. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, Matsumoto A, Stamler JS, Koch WJ: Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 2004; 279: 20655-20662. (Pubitemid 38656460)
100. Burger D, Lei M, Geoghegan-Morphet N, Lu X, Xenocostas A, Feng Q: Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res 2006; 72: 51-59. (Pubitemid 44310637)
101. Gao E, Boucher M, Chuprun JK, Zhou RH, Eckhart AD, Koch WJ: Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol 2007; 293:H60-H68. (Pubitemid 47105059)
102. van der Meer P, Groenveld HF, Januzzi JL Jr, van Veldhuisen DJ: Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009; 95: 1309-1314.
103. Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaidis I, Ikonomidis I, Filippatos G, Kremastinos DT: Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 2008; 155: 751.e1-e7.
104. Palazzuoli A, Silverberg DS, Calabrò A, Spinelli T, Quatrini I, Campagna MS, Franci B, Nuti R: Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia. J Cardiovasc Pharmacol 2009; 53: 462-467.
105. Imamura R, Moriyama T, Isaka Y, Namba Y, Ichimaru N, Takahara S, Okuyama A: Erythropoietin protects the kidneys against ischemia reperfusion injury by activating hypoxia inducible factor-1alpha. Transplantation 2007; 83: 1371-1379. (Pubitemid 46800315)
106. Eto N, Wada T, Inagi R, Takano H, Shimizu A, Kato H, Kurihara H, Kawachi H, Shankland SJ, Fujita T, Nangaku M: Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 2007; 72: 455-463. (Pubitemid 47237606)
107. Guneli E, Cavdar Z, Islekel H, Sarioglu S, Erbayraktar S, Kiray M, Sokmen S, Yilmaz O, Gokmen N: Erythropoietin protects the intestine against ischemia/ reperfusion injury in rats. Mol Med 2007; 13: 509-517. (Pubitemid 47585745)
108. Sayan H, Ozacmak VH, Sen F, Cabuk M, Atik DY, Igdem AA, Ozacmak ID: Pharmacological preconditioning with erythropoietin reduces ischemia-reperfusion injury in the small intestine of rats. Life Sci 2009; 84: 364-371.
109. Maiese K, Chong ZZ, Li F, Shang YC: Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. Prog Neurobiol 2008; 85: 194-213.
110. Arcasoy MO: The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141: 14-31. (Pubitemid 351347536)
111. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, Dammacco F: Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999; 93: 2627-2636. (Pubitemid 29181195)
112. Kertesz N, Wu J, Chen TH, Sucov HM, Wu H: The role of erythropoietin in regulating angiogenesis. Dev Biol 2004; 276: 101-110. (Pubitemid 39452849)
113. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW: Erythropoietin biology in cancer. Clin Cancer Res 2006; 12: 332-339. (Pubitemid 43166118)
114. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner- Rihm C, Martin H, Zeiher AM, Dimmeler S: Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102: 1340-1346 (erratum published in Blood 2004; 103: 4388). (Pubitemid 36988041)
115. Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D: Erythropoietin regulates endothelial progenitor cells. Blood 2004; 103: 921-926. (Pubitemid 38129551)
116. Bahlmann FH, DeGroot K, Duckert T, Niemczyk E, Bahlmann E, Boehm SM, Haller H, Fliser D: Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 2003; 64: 1648-1652. (Pubitemid 37323692)
117. George J, Goldstein E, Abashidze A, Wexler D, Hamed S, Shmilovich H, Deutsch V, Miller H, Keren G, Roth A: Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase- dependent manner. Cardiovasc Res 2005; 68: 299-306. (Pubitemid 41428426)
118. Müller-Ehmsen J, Schmidt A, Krausgrill B, Schwinger RH, Bloch W: Role of erythropoietin for angiogenesis and vasculogenesis: from embryonic development through adulthood. Am J Physiol Heart Circ Physiol 2006; 290:H331-H340.
119. Tsukada H, Ishimitsu T, Ogawa Y, Sugimoto T, Yagi S: Direct vasopressor effects of erythropoietin in genetically hypertensive rats. Life Sci 1993; 52: 1425-1434.
120. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H: Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005; 353: 782-792. (Pubitemid 41215487)
121. Takagi H, Watanabe D, Suzuma K, Kurimoto M, Suzuma I, Ohashi H, Ojima T, Murakami T: Novel role of erythropoietin in proliferative diabetic retinopathy. Diabetes Res Clin Pract 2007; 77(suppl 1):S62-S64. (Pubitemid 47212555)
122. Tsai PT, Ohab JJ, Kertesz N, Groszer M, Matter C, Gao J, Liu X, Wu H, Carmichael ST: A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci 2006; 26: 1269-1274. (Pubitemid 43237059)
123. Chen ZY, Asavaritikrai P, Prchal JT, Noguchi CT: Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation. J Biol Chem 2007; 282: 25875-25883. (Pubitemid 47372832)
124. Katz O, Gil L, Lifshitz L, Prutchi-Sagiv S, Gassmann M, Mittelman M, Neumann D: Erythropoietin enhances immune responses in mice. Eur J Immunol 2007; 37: 1584-1593. (Pubitemid 46939493)
125. Lifshitz L, Prutchi-Sagiv S, Avneon M, Gassmann M, Mittelman M, Neumann D: Non-erythroid activities of erythropoietin: functional effects on murine dendritic cells. Mol Immunol 2009; 46: 713-721.
126. Lifshitz L, Tabak G, Mittelman M, Gassmann M, Neumann D: Macrophages as novel targets for erythropoietin. Haematologica 2010; 95: 1823-1831.
127. Avneon M, Lifshitz L, Katz O, Prutchi-Sagiv S, Gassmann M, Mittelman M, Neumann D: Non-erythroid effects of erythropoietin: are neutrophils a target? Leuk Res 2009; 33: 1430-1432.
128. Mitsuma W, Ito M, Kodama M, Fuse K, Okamura K, Minagawa S, Kato K, Hanawa H, Toba K, Nakazawa M, Aizawa Y: Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis. Biochem Biophys Res Commun 2006; 344: 987-994.
129. Vaupel P: Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 2008; 13(suppl 3):21-26.
130. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ: The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008; 67: 39-61.
131. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M, Hashimoto M, Musha T, Ogawa K, Fujita H, Nakamura Y, Shiozaki H, Utsumi H: Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003; 24: 1021-1029 (erratum published in Carcinogenesis 2003; 24: 1567). (Pubitemid 36833185)
132. Udupa KB: Functional significance of erythropoietin receptor on tumor cells. World J Gastroenterol 2006; 12: 7460-7462. (Pubitemid 46017742)
133. Szenajch J, Wcislo G, Jeong JY, Szczylik C, Feldman L: The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells. Biochim Biophys Acta 2010; 1806: 82-95.
134. Hardee ME, Cao Y, Fu P, Jiang X, Zhao Y, Rabbani ZN, Vujaskovic Z, Dewhirst MW, Arcasoy MO: Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One 2007; 2:e549.
135. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23: 5960-5972.
136. Longmore GD: Do cancer cells express functional erythropoietin receptors? N Engl J Med 2007; 356: 2447. (Pubitemid 46919768)
137. Brower V: Erythropoietin may impair, not improve, cancer survival. Nat Med 2003; 9: 1439. (Pubitemid 38004752)
138. Steensma DP, Loprinzi CL: Erythropoietin use in cancer patients: a matter of life and death? J Clin Oncol 2005; 23: 5865-5868.
139. Sinclair AM, Rogers N, Busse L, Archibeque I, Brown W, Kassner PD, Watson JE, Arnold GE, Nguyen KC, Powers S, Elliott S: Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 2008; 98: 1059-1067. (Pubitemid 351399799)
140. Fandrey J: Erythropoietin receptors on tumor cells: what do they mean? Oncologist 2008; 13(suppl 3):16-20.
141. Katz O, Barzilay E, Skaat A, Herman A, Mittelman M, Neumann D: Erythropoietin induced tumour mass reduction in murine lymphoproliferative models. Acta Haematol 2005; 114: 177-179. (Pubitemid 41540345)
142. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, Spahr C, Um M, Van G, Begley CG: Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006; 107: 1892-1895 (erratum published in Blood 2006; 107: 3454). (Pubitemid 43289368)
143. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG: Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis- stimulating agents in cancer patients. Cancer 2007; 110: 477-488. (Pubitemid 47106135)
144. Farrell F, Lee A: The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004; 9: 18-30. (Pubitemid 39658342)
145. Jelkmann W, Laugsch M: Problems in identifying functional erythropoietin receptors in cancer tissue. J Clin Oncol 2007; 25: 1627-1628. (Pubitemid 46733093)
146. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, Corwin MJ, EPO Critical Care Trials Group: Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357: 965-976. (Pubitemid 47367076)
147. Henry DH, Bowers P, Romano MT, Provenzano R: Epoetin alfa: clinical evolution of a pleiotropic cytokine. Arch Intern Med 2004; 164: 262-276. (Pubitemid 38176466)
148. Kanbay M, Akcay A, Delibasi T, Uz B, Kaya A, Koca C, Turgut F, Bavbek N, Uz E, Duranay M, Yigitoglu R: Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure. Adv Ther 2007; 24: 346-352. (Pubitemid 46988378)
149. Krapf R, Hulter HN: Arterial hypertension induced by erythropoietin and erythropoiesis- stimulating agents (ESA). Clin J Am Soc Nephrol 2009; 4: 470-480.
150. Shi Z, Hodges VM, Dunlop EA, Percy MJ, Maxwell AP, El-Tanani M, Lappin TR: Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Mol Cancer Res 2010; 8: 615-626.
151. Henry DH, Gordan LN, Charu V, Wilhelm FE, Williams D, Xie J, Woodman RC: Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs. weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia. Curr Med Res Opin 2006; 22: 1403-1413. (Pubitemid 44085592)